ENGN
enGene Therapeutics Inc.
Key Financials
Operating Income
$-123165000
↓ 97.7%
EPS (Diluted)
$2.29
↑ 56.8%
Net Income
$-117302000
↓ 112.7%
Total Liabilities
$53.8M
↑ 39.4%
Cash & Equivalents
$50.2M
↓ 71.0%
Total Assets
$221.5M
↓ 28.8%
Shareholders' Equity
$167.7M
↓ 38.5%
Dividends/Share
$0.00
NaN%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/13/2026 | View on SEC |
| SCHEDULE 13G/A | 8/12/2026 | View on SEC |
| 8-K | 8/11/2026 | View on SEC |
| 3 | 7/22/2026 | View on SEC |
| 3 | 7/22/2026 | View on SEC |
| SCHEDULE 13G | 7/22/2026 | View on SEC |
| 8-K | 7/17/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ENGN |
| Company Name | enGene Therapeutics Inc. |
| CIK | 1980845 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1031 |
| State of Incorporation | Z4 |
| Phone | (514) 332-4888 |